Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Vladimir Maletic"'
Publikováno v:
Translational Psychiatry, Vol 13, Iss 1, Pp 1-16 (2023)
Abstract The pathophysiology of major depressive disorder (MDD) is thought to result from impaired connectivity between key brain networks. Gamma-aminobutyric acid (GABA) is the key inhibitory neurotransmitter in the brain, working primarily via GABA
Externí odkaz:
https://doaj.org/article/68754b99e0274125a9655f0b3a197458
Publikováno v:
The Primary Care Companion For CNS Disorders. 25
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33d1fdd15ff09fc97eb98e2b86e46666
https://doi.org/10.4088/pcc.22nr03361
https://doi.org/10.4088/pcc.22nr03361
Autor:
Michael E. Thase, Stephen M. Stahl, Roger S. McIntyre, Tina Matthews-Hayes, Donna Rolin, Mehul Patel, Amanda Harrington, Vladimir Maletic, W. Clay Jackson, Eduard Vieta
Publikováno v:
The Primary Care Companion For CNS Disorders. 25
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c685a150fb837cfdb3e27b38c209ae8c
https://doi.org/10.4088/pcc.22m03322
https://doi.org/10.4088/pcc.22m03322
Autor:
Stefan Schwabe, Alisa R Kosheleff, Peibing Qin, Lilian W. Adeojo, Oyinkansola Odebo, Toyin Adewole, Zhao Wang, Vladimir Maletic, Azmi Nasser
Publikováno v:
Clinical Pharmacology in Drug Development
SPN‐812 (viloxazine extended‐release) is a novel nonstimulant recently approved as a treatment for attention‐deficit/hyperactivity disorder in children and adolescents. Given that SPN‐812 is metabolized by CYP2D6 and may be coadministered wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1af86113cc80951ccedf3f9869520367
http://europepmc.org/articles/PMC8597116
http://europepmc.org/articles/PMC8597116
Publikováno v:
CNS Spectrums. 28:235-235
IntroductionMost ADHD treatments are thought to be effective due to augmentation of dopamine (DA) and norepinephrine (NE). Our prior preclinical studies found that the ADHD treatment, viloxazine, may augment serotonin (5-HT) in addition to NE and DA;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::29c9dbba65b548b9dc9c2f62e7de5759
https://doi.org/10.1017/s1092852923001633
https://doi.org/10.1017/s1092852923001633
Autor:
Nicholas Fry, Shamia L. Faison, Vladimir Maletic, Azmi Nasser, Zhao Wang, Oyinkansola Odebo, Toyin Adewole
Publikováno v:
Journal of Clinical Psychopharmacology
Supplemental digital content is available in the text.
Background Viloxazine extended-release is a novel nonstimulant under investigation as a potential treatment for attention-deficit/hyperactivity disorder (ADHD). Given the potential for vilox
Background Viloxazine extended-release is a novel nonstimulant under investigation as a potential treatment for attention-deficit/hyperactivity disorder (ADHD). Given the potential for vilox
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::694c012548a3bd9b639fa58d0c393a70
https://doi.org/10.1097/jcp.0000000000001361
https://doi.org/10.1097/jcp.0000000000001361
Publikováno v:
International Clinical Psychopharmacology
Patients who experience bipolar depression have diverse demographic and clinical characteristics that have the potential to impact treatment. The efficacy of cariprazine in bipolar I depression was evaluated in patient subgroups defined by baseline d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db85895bfc3877b0cd4c6f56897b503a
https://doi.org/10.1097/yic.0000000000000344
https://doi.org/10.1097/yic.0000000000000344
Publikováno v:
Journal of Experimental Pharmacology. 12:285-300
Background Viloxazine was historically described as a norepinephrine reuptake inhibitor (NRI). Since NRIs have previously demonstrated efficacy in attention deficit/hyperactivity disorder (ADHD), viloxazine underwent contemporary investigation in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a54078f783740fd94a7f2117d34d065
https://doi.org/10.2147/jep.s256586
https://doi.org/10.2147/jep.s256586
Autor:
Felicia Ceban, Susan Ling, Leanna M.W. Lui, Yena Lee, Hartej Gill, Kayla M. Teopiz, Nelson B. Rodrigues, Mehala Subramaniapillai, Joshua D. Di Vincenzo, Bing Cao, Kangguang Lin, Rodrigo B. Mansur, Roger C. Ho, Joshua D. Rosenblat, Kamilla W. Miskowiak, Maj Vinberg, Vladimir Maletic, Roger S. McIntyre
Publikováno v:
Brain, Behavior, and Immunity
Importance COVID-19 is associated with clinically significant symptoms despite resolution of the acute infection (i.e., post-COVID-19 syndrome). Fatigue and cognitive impairment are amongst the most common and debilitating symptoms of post-COVID-19 s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32d201723d06559b9ad212ec0f0fea60
https://pubmed.ncbi.nlm.nih.gov/34973396
https://pubmed.ncbi.nlm.nih.gov/34973396
Autor:
Jonathan Rubin, Frank Lopez, Vladimir Maletic, Alisa R Kosheleff, Gregory D. Busse, Tesfaye Liranso, Azmi Nasser, Joseph T. Hull, Maurizio Fava, Peibing Qin
Publikováno v:
International Journal of Clinical Practice
Aims When clinicians evaluate potential medications for their patients, they must weigh the probability of a treatment's benefits against the possible risks. To this end, the present analyses evaluate the novel nonstimulant viloxazine extended‐rele
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11e1471004d63d0874ac782d8627d7b2
https://doi.org/10.1111/ijcp.14330
https://doi.org/10.1111/ijcp.14330